Acute Treatment of Ischemic Stroke
- PMID: 34798968
- DOI: 10.1016/j.ncl.2021.08.002
Acute Treatment of Ischemic Stroke
Abstract
Ischemic stroke affects 2.5% of the population of the United States and is the leading cause of disability. This article outlines the evidence to support intravenous thrombolysis with alteplase and tenecteplase, thrombolysis in the setting of DWI/flair mismatch, endovascular treatment in the 6-hour and 6- to 24-hour window, and the use of telemedicine in acute stroke. Current controversies and ongoing trials within endovascular treatment are also detailed. Case presentations are included to provide clinical context and the application of data to practice.
Keywords: Acute ischemic stroke; Endovascular treatment; Thrombolysis.
Published by Elsevier Inc.
Conflict of interest statement
Disclosure The authors have nothing to disclose.
Similar articles
-
Evolving Thrombolytics: from Alteplase to Tenecteplase.Neurotherapeutics. 2023 Apr;20(3):664-678. doi: 10.1007/s13311-023-01391-3. Epub 2023 Jun 5. Neurotherapeutics. 2023. PMID: 37273127 Free PMC article. Review.
-
Implementation of Tenecteplase for Acute Ischemic Stroke Treatment.J Emerg Nurs. 2024 Mar;50(2):171-177. doi: 10.1016/j.jen.2023.11.004. Epub 2023 Dec 7. J Emerg Nurs. 2024. PMID: 38069957
-
Tenecteplase to Replace Alteplase? Comparing Thrombolytic Therapies for Acute Ischemic Stroke: June 2023 Annals of Emergency Medicine Journal Club.Ann Emerg Med. 2023 Jun;81(6):759-760. doi: 10.1016/j.annemergmed.2023.04.012. Ann Emerg Med. 2023. PMID: 37210165 No abstract available.
-
Tenecteplase versus alteplase for stroke thrombolysis evaluation (TASTE): A multicentre, prospective, randomized, open-label, blinded-endpoint, controlled phase III non-inferiority trial protocol.Int J Stroke. 2023 Jul;18(6):751-756. doi: 10.1177/17474930231154390. Epub 2023 Feb 2. Int J Stroke. 2023. PMID: 36655938
-
Tenecteplase for the treatment of acute ischemic stroke: A review of completed and ongoing randomized controlled trials.Int J Stroke. 2018 Dec;13(9):885-892. doi: 10.1177/1747493018790024. Epub 2018 Jul 23. Int J Stroke. 2018. PMID: 30035698 Review.
Cited by
-
Kaempferol-3-O-(2″-O-galloyl-β-D-glucopyranoside): a novel neuroprotective agent from Diospryros kaki against cerebral ischemia-induced brain injury.J Nat Med. 2024 Mar;78(2):312-327. doi: 10.1007/s11418-023-01765-z. Epub 2023 Dec 24. J Nat Med. 2024. PMID: 38143256
-
Application of digitization and visualization-based muscle strength measurement in ischemic stroke patients with motor dysfunction.Sci Rep. 2023 Oct 16;13(1):17507. doi: 10.1038/s41598-023-44826-9. Sci Rep. 2023. PMID: 37845368 Free PMC article.
-
Predicting the functional outcome of intensive inpatient rehabilitation after stroke: results from the RIPS Study.Eur J Phys Rehabil Med. 2024 Feb;60(1):1-12. doi: 10.23736/S1973-9087.23.07852-8. Epub 2023 Nov 7. Eur J Phys Rehabil Med. 2024. PMID: 37934187 Free PMC article.
-
A New Perspective in the Treatment of Ischemic Stroke: Ferroptosis.Neurochem Res. 2024 Apr;49(4):815-833. doi: 10.1007/s11064-023-04096-3. Epub 2024 Jan 3. Neurochem Res. 2024. PMID: 38170383 Review.
-
Anti-Inflammatory Effects of Flavonoids in Common Neurological Disorders Associated with Aging.Int J Mol Sci. 2023 Feb 21;24(5):4297. doi: 10.3390/ijms24054297. Int J Mol Sci. 2023. PMID: 36901731 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical